Gamida Cell is an Israeli company specializing in cellular and immune therapies for the treatment of cancer and orphan genetic diseases. Its lead product, NiCord®, offers patients in need of HSCT an alternative to the existing approach of bone marrow transplant by using ex vivo expansion of cord blood. In clinical trials so far, NiCord® has demonstrated rapid engraftment and clinical outcomes that appear comparable to transplantation of peripheral blood.
NiCord®, CordIn™ and other products under development by Gamida Cell, all utilize the company’s proprietary NAM platform technology to expand cells while preserving and enhancing their functionality. [Read more…]